Alnylam Pharmaceuticals Cash Flow Statement
NASDAQ: ALNYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
232.68+8.15 (+3.63%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Alnylam Pharmaceuticals free cash flow
In fiscal 2025, Alnylam Pharmaceuticals generated $524.1 million of operating cash flow and spent $58.7 million on capital expenditures. That left free cash flow of $465.4 million, a free-cash-flow margin of 12.5% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Alnylam Pharmaceuticals cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 313.75M | -278.16M | -440.24M | -1.13B | -852.82M | -858.28M | -886.12M | -761.50M | -490.87M | -410.11M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 55.66M | 56.67M | 54.05M | 44.47M | 47.57M | 34.77M | 17.18M | 15.25M | 13.37M | 15.13M |
| Stock-Based Compensation | 348.24M | 272.08M | 221.68M | 230.65M | 165.72M | 139.87M | 174.84M | 157.75M | 92.82M | 75.53M |
| Change in Working Capital | -444.78M | -214.08M | 57.26M | 7.62M | -122.47M | 21.12M | 418.43M | -39.61M | -34.47M | 4.40M |
| Operating Cash Flow | 524.08M | -8.31M | 104.16M | -541.27M | -641.69M | -614.96M | -278.43M | -562.62M | -382.79M | -307.70M |
| Capital Expenditures | -58.70M | -34.28M | -62.21M | -72.06M | -76.37M | -70.36M | -140.16M | -126.89M | -104.21M | -64.56M |
| Investing Cash Flow | 436.33M | -116.84M | -336.35M | 169.35M | -273.30M | -435.52M | -417.68M | 272.94M | -290.36M | 142.59M |
| Debt Repaid | — | — | — | -762.11M | 0 | 0 | — | — | — | — |
| Financing Cash Flow | -305.19M | 294.16M | 172.13M | 425.75M | 1.25B | 994.98M | 823.18M | 65.47M | 1.12B | 177.83M |
| Net Change in Cash | 690.15M | 153.77M | -53.67M | 46.40M | 323.11M | -50.58M | 127.00M | -224.20M | 451.74M | 12.72M |
| Free Cash Flow | 465.38M | -42.59M | 41.95M | -613.33M | -718.07M | -685.32M | -418.58M | -689.50M | -487.00M | -372.26M |
This table shows 10 annual periods of Alnylam Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2016, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ALNY's reporting calendar. What is a cash flow statement?